A total of $700,000 was raised by Bot M.D., an AI chatbot app developer for doctors, in seed funding from Y Combinator and angels, including Steve Blank, one of the inventors of the Lean Startup method.
Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.
Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
Boston-based Vertex Pharmaceuticals has more than doubled their research facility in San Diego where they first discovered their key Cystic Fibrosis Drug adding more than 90000 sq ft. to it. The total facility will be now 170,000 sq. ft improving the pharma giant's capability to achieve the next generation of blockbusters.
The startup also revealed its new research on Textray, which the company claims to be the “most comprehensive Artificial Intelligent research till now.” This is all working towards developing their new product which is currently capable of identifying 40 clinical findings as a result of training via 2 million images.
MyHeritage helps users find their ancestry line, search historical records and build family trees in their service called MyHeritage DNA, launched in 2016. Other such sites providing the same services are 23andMe and Ancestry.com. The company users are asked to send saliva sample for genetic analysis and nearly 1.4 million customers have participated in the DNA test.
According to the FDA, if the antidote drugs are used on a patient, they could suffer from “allergic reactions, local irritation” and a wide number of cardiovascular issues, including restriction of blood supply to tissues. The FDA stated that there has not yet been any reports of patient harm from Naloxone.
GE Healthcare has been roped in by Tampa General Hospital for the building of a new care coordination center for using the power of predictive analytics for working across the spectrum of quality and experience improvement projects at the hospital meant for patients, families and staff alike.
This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.